94 related articles for article (PubMed ID: 28008195)
1. A multicenter survey of stage T1 glottic cancer treated with radiotherapy delivered in 2.25-Gy fractions in clinical practice: An initial 5-year analysis.
Itoh Y; Kubota S; Kawamura M; Nomoto Y; Murao T; Yamakawa K; Ishihara S; Hirasawa N; Asano A; Yanagawa S; Naganawa S
Nagoya J Med Sci; 2016 Dec; 78(4):399-406. PubMed ID: 28008195
[TBL] [Abstract][Full Text] [Related]
2. Poor local control of ulcerative T1 glottic cancer treated with 2.25-Gy per fraction radiotherapy.
Oie Y; Itoh Y; Kawamura M; Takase Y; Murao T; Ishihara S; Nomoto Y; Hirasawa N; Asano A; Yamakawa K; Ito J; Kinoshita F; Naganawa S
Nagoya J Med Sci; 2021 Nov; 83(4):811-825. PubMed ID: 34916724
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction.
Lee TH; Lee JH; Kwon SK; Chung EJ; Wu HG
Radiat Oncol J; 2022 Jun; 40(2):120-126. PubMed ID: 35796115
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
6. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
7. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of acute/late toxicity and local recurrence in T1-T2 glottic carcinoma treated with accelerated hypofractionated 3D-conformal external beam radiotherapy (3D-CRT).
Kouloulias VE; Zygogianni A; Mosa E; Platoni K; Georgakopoulos J; Antypas C; Beli I; Tolia M; Maragoudakis P; Giotakis I; Papas Z; Psyrri A; Kelekis N; Kouvaris J
Radiol Oncol; 2013 Jun; 47(2):185-91. PubMed ID: 23801916
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution.
Laskar SG; Baijal G; Murthy V; Chilukuri S; Budrukkar A; Gupta T; Agarwal JP
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e180-6. PubMed ID: 22862908
[TBL] [Abstract][Full Text] [Related]
10. 3D conformal hypofractionated radical radiotherapy in early glottic cancer.
Amado AC; Bujor L; Monteiro Grillo I
Rep Pract Oncol Radiother; 2013 May; 18(5):261-4. PubMed ID: 24416562
[TBL] [Abstract][Full Text] [Related]
11. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
12. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
14. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
Kupelian PA; Willoughby TR
Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
16. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
18. Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
Ortholan C; Ramaioli A; Peiffert D; Lusinchi A; Romestaing P; Chauveinc L; Touboul E; Peignaux K; Bruna A; de La Roche G; Lagrange JL; Alzieu C; Gerard JP
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):479-85. PubMed ID: 15890590
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for local control of early glottic squamous cell carcinomas after definitive radiotherapy.
Okubo M; Itonaga T; Saito T; Shiraishi S; Mikami R; Sakurada A; Sugahara S; Park J; Tokuuye K; Saito K
Mol Clin Oncol; 2020 Jun; 12(6):541-550. PubMed ID: 32337036
[TBL] [Abstract][Full Text] [Related]
20. Optimized radiotherapy treatment strategy for early glottic carcinoma.
Ono T; Itoh Y; Ishihara S; Kawamura M; Oie Y; Takase Y; Okumura M; Oyoshi H; Nagai N; Naganawa S
Nagoya J Med Sci; 2023 May; 85(2):241-254. PubMed ID: 37346844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
